Uterine cancer affects 28 in 100,000 women annually. Learn the 5 critical warning signs that could save your life and why ...

Endometrial cancer (cancer in the lining of the uterus ... This study is the first to examine blood markers that could help ...

This article will describe the most salient molecular markers that have been identified in uterine serous cancer, thus far with emphasis on the use of erbB2 (HER2/neu) as the first of a series of ...

including endometrioid endometrial carcinomas (EEC). Trop-2 overexpression has been proposed as a marker for biologically aggressive tumor phenotypes. Methods Trop-2 protein expression was ...

A retrospective study showed that either folate receptor alpha or B7-H4 was expressed in more than 80% of endometrial cancers ...

Endometrial cancer is one of the few cancers that doesn’t stay quiet. That’s why you should never brush off spotting between periods or any bleeding after menopause. When caught early ...

Ultimately, these biomarkers can be used as selection markers for patient stratification. Since mutations in CTNNB1 occur at relatively high frequency in endometrial cancer and hepatocellular ...

Uterine cancer is the fourth most common cancer among women and the most common cancer of a woman's reproductive system. There are two major types of uterine cancer: Adenocarcinoma of the endometrium: ...

The following is a summary of “Disparities in clinical drug trial participation in endometrial cancer: a real-world analysis, ...

Adding GLP-1s to progestin therapy appeared to reduce the risk for endometrial cancer among women with benign uterine or endometrial hyperplasia. Further research is needed to better understand ...

GSK’s PD-1 inhibitor Jemperli has been cleared for use by the NHS as a first-line treatment for a specific type of endometrial cancer, making it an option for around 580 women across England ...